 The FDA has signed off DiaMedica Therapeutics Incs NASDAQ: DMAC Investigational New Drug IND application to proceed with a pivotal Phase 23 study of DM199 recombinant human tissue kallikrein-1or KLK1 for the treatment of patients with Acute Ischemic Stroke AIS. The upcoming pivotal ReMEDy2 trial will evaluate whether DM199 can improve three-month outcomes in AIS patients without other treatment options. 